Independent
Tenure on this board
7.7 yrs
3 nominees · 3 ballot items.
The 2025 Arcadia Biosciences annual meeting will consider three management-proposed items: election of three Class I directors, an advisory vote on executive compensation, and ratification of the independent auditors.
Election of Albert D. Bolles, Kevin Comcowich and Thomas J. Schaefer as Class I directors to serve three-year terms expiring at the 2028 Annual Meeting and until their successors are duly elected or until their resignation, death or removal.
Advisory, non-binding vote to approve the compensation of Arcadia's named executive officers as disclosed in the Proxy Statement for 2025.
Ratify Deloitte & Touche LLP as Arcadia's independent registered public accounting firm for the fiscal year ending December 31, 2025.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 7.75% | 159,390 | $220K |
| 2 | SABBY MANAGEMENT, LLC | 5.57% | 114,554 | $158K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 1.52% | 31,323 | $43K |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.61% | 12,614 | $17K |
| 5 | STATE STREET CORP | 0.59% | 12,146 | $17K |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 0.47% | 9,644 | $13K |
| 7 | VANGUARD FIDUCIARY TRUST CO | 0.21% | 4,394 | $6K |
| 8 | Tower Research Capital LLC (TRC | 0.19% | 3,940 | $5K |
| 9 | UBS Group AG | 0.04% | 772 | $1K |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.02% | 420 | $579 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.